Brief: Acticor Biotech/Glenzocimab: Analysis Of Primary And Secondary Endpoints Of Phase 2/3 Actisave Showed No Improved Efficacy

Acticor Biotech SA

25/04/2024 07:04

April 25 (Reuters) - Acticor Biotech SA  ALACT.PA :
    * ACTICOR BIOTECH: TOPLINE RESULTS OF ACTISAVE PHASE 2/3
STUDY IN
STROKE TREATMENT
    * NO EVIDENCE OF EFFICACY FOR EITHER PRIMARY ENDPOINT,
PROPORTION
OF PATIENTS WITH SEVERE DISABILITY OR DEATH (MRS 4-6) AT 90 DAYS
AFTER STROKE, OR FOR SECONDARY ENDPOINT, PROPORTION OF PATIENTS
WITH NO DISABILITY (MRS 0-2) AT 90 DAYS.
    * ANALYSIS OF PRIMARY AND SECONDARY ENDPOINTS OF PHASE 2/3
ACTISAVE STUDY SHOWED NO IMPROVED EFFICACY WITH GLENZOCIMAB

Source text for Eikon:  ID:nBwbNcxhsa 
Further company coverage:  ALACT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))